Application No. 09/687,384 Attorney Docket No. 08680-0013

Applicants' undersigned representative encourages the Examiner to call if any additional information is required to allow these claims.

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Dated: April 10, 2003

By:

Sean Myers-Payne


Reg. No. 42,920 ph. (571) 203-2717

fax (202) 408-4400

sean.myers-payne@finnegan.com

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com





Appendix to Amendment

The claims are amended as follows:

- 1. (ONCE AMENDED) A method for preventing or treating gastrointestinal disease comprising administering an effective amount of [racemic pindolol or] S (-) pindolol, or a salt thereof, to a subject in need thereof.
- 4. (ONCE AMENDED) [A] <u>The</u> method according to claim 1, [in which] <u>wherein</u> an effective [amounts] <u>amount</u> of [RS-pindolol or] S(-) pindolol, or [their] <u>its</u> salts, [are] <u>is</u> administered in a pharmaceutical dosage form that permits rapid release of the [active substances] <u>S(-) pindolol</u>.
- 5. (ONCE AMENDED) [A] <u>The</u> method according to claim 1, [in which] <u>wherein</u> an effective [amounts] <u>amount</u> of [RS pindolol or] <u>the</u> S(-) pindolol, or [their] <u>its</u> salts, [are] <u>is</u> administered in a pharmaceutical dosage form that releases the [active substances] <u>S(-) pindolol</u> in a slow or controlled fashion.
- 6. (ONCE AMENDED) [A] <u>The</u> method according to claim 1, [in which] <u>wherein</u> the gastrointestinal diseases are [characterised as] <u>selected from</u> non-ulcerative dyspepsia, [or] irritable bowel syndrome, or chemotherapy-associated disorders of motility[, including nausea].
- 7. (NEW) The method according to claim 6, wherein the chemotherapy-associated disorders of motility include nausea.

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com